Betty R Ferrell1, Carly L Paterson2, Mark T Hughes3, Vincent Chung1, Marianna Koczywas1, Thomas J Smith3. 1. 1 Division of Nursing Research and Education , Department of Population Sciences, City of Hope, Duarte, California. 2. 2 National Cancer Institute, National Institutes of Health , Rockville, Maryland. 3. 3 Sidney Kimmel Comprehensive Cancer Center of Johns Hopkins Medical Institutions , Baltimore, Maryland.
Abstract
INTRODUCTION:Advanced cancer patients participating in phase 1 clinical trials experience considerable symptom burden. Palliative care (PC) may benefit these individuals by providing supportive care during clinical research participation. This study investigates integration of a PC intervention among phase 1 trial participants with advanced cancer. METHODS AND MATERIALS: This study is a multisite randomized clinical trial testing a concurrent PC intervention among phase 1 trial participants. Baseline demographic and clinical characteristics and descriptive baseline assessment findings were examined for all participants to date. Self-report assessments included quality of life (QOL) using the Functional Assessment of Cancer Therapy-General, spirituality using the Functional Assessment of Chronic Illness Therapy-Spirituality, and overall distress using the Distress Thermometer. Clinical trial retention and healthcare utilization were assessed through chart audit at study completion. RESULTS: The study has enrolled 178 participants to date. The average age is 60.3 years, the majority was Caucasian (57.9%), and participants had an average of 1.7 comorbidities. Overall QOL was 77.6 (±15.1). Responses were most favorable for social/family well-being (22.6 ± 4.6), lowest for emotional well-being (14.9 ± 5.1), and average overall distress was 3.6 (±2.7). Healthcare utilization at study completion (n = 134) identified low rates of supportive care referrals, with approximately half of participants referred to social work (50.8%), and fewer referred for pain (43%), resource centers (44%), and physical therapy (18%). CONCLUSION: Phase 1 clinical trial participants experience unmet QOL needs at baseline and levels of distress that merit clinical intervention. Although this study is in progress, initial findings support the potential benefits of PC among this population.
RCT Entities:
INTRODUCTION: Advanced cancerpatients participating in phase 1 clinical trials experience considerable symptom burden. Palliative care (PC) may benefit these individuals by providing supportive care during clinical research participation. This study investigates integration of a PC intervention among phase 1 trial participants with advanced cancer. METHODS AND MATERIALS: This study is a multisite randomized clinical trial testing a concurrent PC intervention among phase 1 trial participants. Baseline demographic and clinical characteristics and descriptive baseline assessment findings were examined for all participants to date. Self-report assessments included quality of life (QOL) using the Functional Assessment of Cancer Therapy-General, spirituality using the Functional Assessment of Chronic Illness Therapy-Spirituality, and overall distress using the Distress Thermometer. Clinical trial retention and healthcare utilization were assessed through chart audit at study completion. RESULTS: The study has enrolled 178 participants to date. The average age is 60.3 years, the majority was Caucasian (57.9%), and participants had an average of 1.7 comorbidities. Overall QOL was 77.6 (±15.1). Responses were most favorable for social/family well-being (22.6 ± 4.6), lowest for emotional well-being (14.9 ± 5.1), and average overall distress was 3.6 (±2.7). Healthcare utilization at study completion (n = 134) identified low rates of supportive care referrals, with approximately half of participants referred to social work (50.8%), and fewer referred for pain (43%), resource centers (44%), and physical therapy (18%). CONCLUSION: Phase 1 clinical trial participants experience unmet QOL needs at baseline and levels of distress that merit clinical intervention. Although this study is in progress, initial findings support the potential benefits of PC among this population.
Entities:
Keywords:
clinical trials; oncology; palliative care; palliative care intervention
Authors: K Beernaert; K Pardon; L Van den Block; D Devroey; M De Laat; K Geboes; V Surmont; L Deliens; J Cohen Journal: Eur J Cancer Care (Engl) Date: 2016-06-07 Impact factor: 2.520
Authors: Jeffrey S Weber; Laura A Levit; Peter C Adamson; Suanna Bruinooge; Howard A Burris; Michael A Carducci; Adam P Dicker; Mithat Gönen; Stephen M Keefe; Michael A Postow; Michael A Thompson; David M Waterhouse; Susan L Weiner; Lynn M Schuchter Journal: J Clin Oncol Date: 2014-12-15 Impact factor: 44.544
Authors: Betty R Ferrell; Jennifer S Temel; Sarah Temin; Erin R Alesi; Tracy A Balboni; Ethan M Basch; Janice I Firn; Judith A Paice; Jeffrey M Peppercorn; Tanyanika Phillips; Ellen L Stovall; Camilla Zimmermann; Thomas J Smith Journal: J Clin Oncol Date: 2016-10-28 Impact factor: 44.544
Authors: Esmé Finlay; Hien L Lu; Hope R Henderson; Hope Henderson; Peter J O'Dwyer; David J Casarett Journal: Cancer Date: 2009-01-15 Impact factor: 6.860
Authors: Michelle A Mollica; Erin E Kent; Kathleen M Castro; Erin M Ellis; Rebecca A Ferrer; Angela L Falisi; Anna Gaysynsky; Grace C Huang; Martha A Palan; Wen-Ying Sylvia Chou Journal: J Palliat Med Date: 2018-02-01 Impact factor: 2.947
Authors: Fabiana Bolela; Roberta de Lima; Ana Carolina de Souza; Michele Rocha Moreira; Ana Julia de Oliveira Lago; Giovana Paula Rezende Simino; Jakeline Silva de Araújo Journal: Rev Lat Am Enfermagem Date: 2022